股本结构
单位：万股
| 公告日期 | 2025-10-28 | 2025-10-28 | 2025-07-29 | 2025-07-29 | 2025-04-30 | 2025-04-30 |
|---|---|---|---|---|---|---|
| 证券总股本 | 2890.46 | 2888.97 | 2872.62 | 2870.81 | 2853.32 | 2853.16 |
| 普通股本 | 2890.46 | 2888.97 | 2872.62 | 2870.81 | 2853.32 | 2853.16 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-10-24 | 2025-09-30 | 2025-07-24 | 2025-06-30 | 2025-04-21 | 2025-04-15 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-10-28 | 2890.46 | 未披露 | 定期报告 | 2025-10-24 |
| 2025-10-28 | 2888.97 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Common stock issued pursuant to stock option exercises
Vested restricted stock units converted to common stock
Issuance of common stock in ATM offering, net of issuance costs
|
2025-09-30 |
| 2025-07-29 | 2872.62 | 未披露 | 定期报告 | 2025-07-24 |
| 2025-07-29 | 2870.81 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Common stock issued pursuant to stock option exercises
Vested restricted stock units converted to common stock
Issuance of common stock pursuant to employee stock purchase plan
|
2025-06-30 |
| 2025-04-30 | 2853.32 | 未披露 | 定期报告 | 2025-04-21 |
| 2025-04-30 | 2853.16 | 未披露 | 定期报告 | 2025-04-15 |
| 2025-04-30 | 2853.03 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Vested restricted stock units converted to common stock
Common stock issued pursuant to stock option exercises
Issuance of common stock in ATM offering, net of issuance costs
|
2025-03-31 |
| 2025-02-20 | 2806.83 | 未披露 | 定期报告 | 2025-02-14 |
| 2025-02-20 | 2801.65 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Common stock issued pursuant to stock option exercises
Issuance of common stock in ATM offering, net of issuance costs
Common stock issued pursuant to Perceptive warrant exercise
Vested restricted stock units converted to common stock
Common stock issued pursuant to employee stock purchase plan
|
2024-12-31 |
| 2024-10-29 | 2747.14 | 未披露 | 定期报告 | 2024-10-22 |
| 2024-10-29 | 2743.38 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Common stock issued pursuant to stock option exercises
Vested restricted stock units converted to common stock
Issuance of common stock in ATM offering, net of issuance costs
|
2024-09-30 |
| 2024-07-30 | 2693.59 | 未披露 | 定期报告 | 2024-07-22 |
| 2024-07-30 | 2692.64 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Common stock issued pursuant to stock option exercises
Vested restricted stock units converted to common stock
Common stock issued pursuant to Perceptive warrant exercise
|
2024-06-30 |
| 2024-04-29 | 2615.09 | 未披露 | 定期报告 | 2024-04-24 |
| 2024-04-29 | 2614.17 | 未披露 | 定期报告 | 2024-04-22 |
| 2024-04-29 | 2614.17 | 未披露 | 定期报告 | 2024-04-15 |
| 2024-04-29 | 2612.23 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Common stock issued pursuant to stock option exercises
Vested restricted stock units converted to common stock
|
2024-03-31 |
| 2024-02-23 | 2605.36 | 未披露 | 定期报告 | 2024-02-20 |
| 2024-02-23 | 2597.89 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Common stock issued pursuant to stock option exercises
Vested restricted stock units converted to common stock
Issuance of Class A common shares in registered direct offering, net of issuance costs
Issuance of Class A common shares for the first Milestone Payment
Fractional shares adjustment
Issuance of Class A common shares in underwritten public offering, net of issuance costs
|
2023-12-31 |
| 2023-11-03 | 2588.43 | 未披露 | 定期报告 | 2023-10-30 |
| 2023-11-03 | 2587.54 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Vested restricted stock units converted to common stock
|
2023-09-30 |
| 2023-08-08 | 2577.33 | 未披露 | 定期报告 | 2023-08-01 |
| 2023-08-08 | 2576.11 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Vested restricted stock units converted to common stock
Fractional shares issued upon Reverse Stock Split
Issuance of Class A common shares in registered direct offering, net of issuance costs
Issuance of Class A common shares for the first Milestone Payment
|
2023-06-30 |
| 2023-04-28 | 2418.94 | 未披露 |
更多>>
On April 24, 2023, the Board approved the reverse stock split at a ratio of 1-for-33 (the “Reverse Stock Split”).
|
2023-05-04 |
| 2023-03-31 | 79825.09 | 未披露 | 定期报告 | 2023-03-24 |
| 2023-03-16 | 79824.73 | 未披露 | 定期报告 | 2023-03-14 |
| 2023-03-31 | 79740.27 | 未披露 | 定期报告 | 2023-01-31 |
| 2023-03-16 | 38851.11 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Common stock issued pursuant to stock option exercises
Shares issued for PIPE, net of issuance costs
Shares issued for acquisition
Vested restricted stock units converted to common stock
|
2022-12-31 |
| 2022-11-14 | 38679.51 | 未披露 | 定期报告 | 2022-11-04 |
| 2022-11-14 | 38142.89 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Stock option exercises
Vested restricted stock units converted to common stock
|
2022-09-30 |
| 2022-08-15 | 38064.15 | 未披露 | 定期报告 | 2022-08-09 |
| 2022-08-15 | 37989.68 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Stock option exercises
Shares issued for PIPE, net of issuance costs
Shares issued for acquisition
Vested restricted stock units converted to common stock
|
2022-06-30 |
| 2022-05-03 | 37724.92 | 未披露 | 定期报告 | 2022-04-30 |
| 2022-05-12 | 24515.45 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Stock option exercises
Vested restricted stock units converted to common stock
|
2022-03-31 |
| 2022-03-31 | 24501.64 | 未披露 | 定期报告 | 2022-03-22 |
| 2022-03-14 | 24495.98 | 未披露 | 定期报告 | 2022-03-07 |
| 2022-03-15 | 24472.72 | 未披露 | 定期报告 | 2022-02-22 |
| 2022-03-14 | 24264.76 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Stock option exercises
Conversion of Preferred Stock
Conversion of Class B Common Stock
Net equity infusion from the Business Combination
Vested restricted stock units converted to common stock
|
2021-12-31 |
| 2021-11-15 | 24126.14 | 未披露 | 定期报告 | 2021-11-08 |
| 2021-11-15 | 24019.04 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Conversion of Preferred Stock
Conversion of Class B Common Stock
Net equity infusion from the Business Combination
|
2021-09-30 |
| 2021-08-04 | 24019.04 | 未披露 | 定期报告 | 2021-07-28 |
| 2021-07-19 | 23826.65 | 未披露 |
更多>>
On February 9, 2021, the Company and its wholly owned subsidiary, S-IV Sub, Inc. (“Merger Sub”), entered into an Agreement and Plan of Merger with Mount Sinai Genomics, Inc. d/b/a Sema4 (“Sema4”) (the “Merger Agreement”). If the Merger Agreement is approved by Company stockholders at the Special Meeting (and all other conditions pursuant to the Merger Agreement are either satisfied or waived) Merger Sub will merge with and into Sema4, with Sema4 surviving the merger as a wholly owned subsidiary of the Company.
|
2021-07-23 |
| 2021-05-05 | 5534.38 | 未披露 |
更多>>
from July 10, 2020 to December 31, 2020
Sale of 44,275,000 Units, net of underwriting discounts
Issuance of Class B common stock to initial stockholders
Common stock subject to possible redemption
|
2020-12-31 |
| 2020-11-16 | 5534.38 | 未披露 | 定期报告 | 2020-11-04 |
| 2020-09-03 | 4812.50 | 未披露 | 定期报告 | 2020-10-26 |
From June 30, 2025 to September 30, 2025
Common stock issued pursuant to stock option exercises
Vested restricted stock units converted to common stock
Issuance of common stock in ATM offering, net of issuance costs
From March 31, 2025 to June 30, 2025
Common stock issued pursuant to stock option exercises
Vested restricted stock units converted to common stock
Issuance of common stock pursuant to employee stock purchase plan
From December 31, 2024 to March 31, 2025
Vested restricted stock units converted to common stock
Common stock issued pursuant to stock option exercises
Issuance of common stock in ATM offering, net of issuance costs
From December 31, 2023 to December 31, 2024
Common stock issued pursuant to stock option exercises
Issuance of common stock in ATM offering, net of issuance costs
Common stock issued pursuant to Perceptive warrant exercise
Vested restricted stock units converted to common stock
Common stock issued pursuant to employee stock purchase plan
From June 30, 2024 to September 30, 2024
Common stock issued pursuant to stock option exercises
Vested restricted stock units converted to common stock
Issuance of common stock in ATM offering, net of issuance costs
From March 31, 2024 to June 30, 2024
Common stock issued pursuant to stock option exercises
Vested restricted stock units converted to common stock
Common stock issued pursuant to Perceptive warrant exercise
From December 31, 2023 to March 31, 2024
Common stock issued pursuant to stock option exercises
Vested restricted stock units converted to common stock
From December 31, 2022 to December 31, 2023
Common stock issued pursuant to stock option exercises
Vested restricted stock units converted to common stock
Issuance of Class A common shares in registered direct offering, net of issuance costs
Issuance of Class A common shares for the first Milestone Payment
Fractional shares adjustment
Issuance of Class A common shares in underwritten public offering, net of issuance costs
From June 30, 2023 to September 30, 2023
Vested restricted stock units converted to common stock
From March 31, 2023 to June 30, 2023
Vested restricted stock units converted to common stock
Fractional shares issued upon Reverse Stock Split
Issuance of Class A common shares in registered direct offering, net of issuance costs
Issuance of Class A common shares for the first Milestone Payment
On April 24, 2023, the Board approved the reverse stock split at a ratio of 1-for-33 (the “Reverse Stock Split”).
From December 31, 2021 to December 31, 2022
Common stock issued pursuant to stock option exercises
Shares issued for PIPE, net of issuance costs
Shares issued for acquisition
Vested restricted stock units converted to common stock
From June 30, 2022 to September 30, 2022
Stock option exercises
Vested restricted stock units converted to common stock
From March 31, 2022 to June 30, 2022
Stock option exercises
Shares issued for PIPE, net of issuance costs
Shares issued for acquisition
Vested restricted stock units converted to common stock
From December 31, 2021 to March 31, 2022
Stock option exercises
Vested restricted stock units converted to common stock
From December 31, 2020 to December 31, 2021
Stock option exercises
Conversion of Preferred Stock
Conversion of Class B Common Stock
Net equity infusion from the Business Combination
Vested restricted stock units converted to common stock
From June 30, 2021 to September 30, 2021
Conversion of Preferred Stock
Conversion of Class B Common Stock
Net equity infusion from the Business Combination
On February 9, 2021, the Company and its wholly owned subsidiary, S-IV Sub, Inc. (“Merger Sub”), entered into an Agreement and Plan of Merger with Mount Sinai Genomics, Inc. d/b/a Sema4 (“Sema4”) (the “Merger Agreement”). If the Merger Agreement is approved by Company stockholders at the Special Meeting (and all other conditions pursuant to the Merger Agreement are either satisfied or waived) Merger Sub will merge with and into Sema4, with Sema4 surviving the merger as a wholly owned subsidiary of the Company.
from July 10, 2020 to December 31, 2020
Sale of 44,275,000 Units, net of underwriting discounts
Issuance of Class B common stock to initial stockholders
Common stock subject to possible redemption